Dr. Shamsuddin was a Professor of Pathology for 43 years at the University of Maryland School of Medicine, where he conducted research in cancer prevention and early detection of cancer.

He developed a rapid test kit to screen for an altered carbohydrate, TF-antigen, present in many cancers and pre-cancerous lesions. This technology is the core of OncoVue’s screening technology. In addition, Dr. Shamsuddin oversaw the development and commercialization of IP-6, an anti-cancer agent that also offers other ancillary health benefits. Prior to that, he was a Senior Scientist at the Laboratories of Experimental Pathology and Human Carcinogenesis, National Cancer Institute.

Dr. Shamsuddin, a Board-Certified pathologist also holds a Ph.D. from the University of Maryland and earned an M.B., B.S. (M.D) from Dhaka Medical College, University of Dhaka. Following training in Pathology at the Johns Hopkins- and University of Maryland-affiliated hospitals, he was certified by the American Board of Pathology.